I am a
Home I AM A Search Login

Papers of the Week

2019 Dec 12

Cochrane Database Syst Rev



Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn’s disease.


Davies SC, Nguyen TM, Parker CE, MacDonald JK, Jairath V, Khanna R
Cochrane Database Syst Rev. 2019 Dec 12; 12(12):CD012804.
PMID: 31828765.


Ustekinumab and briakinumab are monoclonal antibodies that target the standard p40 subunit of cytokines interleukin-12 and interleukin-23 (IL-12/23p40), which are involved in the pathogenesis of Crohn's disease (CD). A significant proportion of people with Crohn's disease fail conventional therapy or therapy with biologics (e.g. infliximab) or develop significant adverse events. Anti-IL-12/23p40 antibodies such as ustekinumab may be an effective alternative for these individuals.